Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
412 studies found for:    "Myelofibrosis"
Show Display Options
Rank Status Study
21 Active, not recruiting Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: A: Fludarabine + Busulphan;   Drug: B: Fludarabine + Thiotepa
22 Completed Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: arsenic trioxide;   Drug: cytarabine
23 Recruiting A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: Ruxolitinib;   Drug: Thalidomide
24 Completed Allogeneic Stem Cell Transplantation (SCT) After Dose-reduced Conditioning for Myelofibrosis Patients
Condition: Myelofibrosis
Intervention: Procedure: Allogeneic Stem Cell Transplantation
25 Recruiting Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg
Condition: Myelofibrosis
Interventions: Drug: Ruxolotinib;   Drug: peg-IFN alpha -2a
26 Terminated
Has Results
A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
Condition: Primary Myelofibrosis
Intervention: Drug: Ruxolitinib
27 Completed A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM)
Conditions: Myelofibrosis;   Myeloid Metaplasia
Intervention: Drug: zoledronic acid
28 Completed Thalidomide in Treating Patients With Myelofibrosis
Condition: Primary Myelofibrosis
Interventions: Drug: thalidomide;   Other: laboratory biomarker analysis
29 Active, not recruiting A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: INC424;   Drug: BKM120
30 Completed
Has Results
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
Condition: Myelofibrosis
Interventions: Drug: Ruxolitinib;   Drug: Placebo
31 Completed
Has Results
Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial
Condition: Myelofibrosis
Interventions: Drug: INC424/INCB018424;   Drug: Best Available Therapy (BAT)
32 Active, not recruiting
Has Results
Decitabine in Treating Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Drug: Decitabine;   Other: Laboratory Biomarker Analysis
33 Recruiting P1101 in Treating Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Other: Laboratory Biomarker Analysis;   Biological: PEG-Proline-Interferon Alfa-2b;   Other: Quality-of-Life Assessment
34 Completed A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: TG101348
35 Completed Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia
Condition: Myelofibrosis
Intervention: Drug: Obatoclax mesylate (GX15-070MS)
36 Withdrawn A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis
Condition: Primary Myelofibrosis
Intervention: Biological: Pacritinib
37 Recruiting Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Drug: Ruxolitinib Phosphate;   Drug: Sirolimus;   Drug: Tacrolimus
38 Terminated Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.
Condition: Early Myelofibrosis With High Molecular Risk Mutations
Interventions: Drug: Ruxolitinib;   Drug: Ruxolitinib Placebo
39 Active, not recruiting
Has Results
Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence
Condition: Primary Myelofibrosis
Interventions: Drug: Pomalidomide 0.5 mg;   Drug: Placebo
40 Not yet recruiting Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis
Condition: Secondary Myelofibrosis
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Glycosylated Recombinant Human G-CSF AVI-014;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.